Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SR57667B · 4 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| SR57667B | DRUG | - |
Inclusion Criteria: * Male / female outpatients. * Age \> 50 years at screening. * Dementia of Alzheimer's Type (DSM-IV 290.0) according to DSM-IV criteria, Probable AD according to NINCDS-ADRDA criteria, Mini-Mental State Examination score \> 12 and \< 26. * Untreated or treated for a minimum of 6...
Top 20 of 24 competitors
SR57667B is an investigational small molecule being studied for the treatment of Alzheimer's disease and Parkinson's disease. It is in Phase 2 clinical development, with completed trials in both neurological conditions. The drug is not approved and remains under investigation.
SR57667B is being developed by Sanofi, a multinational pharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting Phase 2 clinical trials to evaluate the drug's effects in patients with Alzheimer's disease and Parkinson's disease.
SR57667B is in Phase 2 clinical development. All four clinical trials for this drug have been completed, including studies in Alzheimer's disease and Parkinson's disease. The drug is investigational and has not received FDA approval.
SR57667B has completed four Phase 2 trials. These include NCT00220272 and NCT00228150 in Parkinson's disease, and NCT00285025 and NCT00285077 in Alzheimer's disease. The trials enrolled a total of 890 participants across multiple countries.
No alternative names for SR57667B have been reported. The drug is identified solely by its code name SR57667B in clinical trial registries and development programs by Sanofi.